Cronos Group Inc. CRON shares have fallen 74.84% in the last 12 months.
On Monday, the company announced it is postponing the release of its financial results again. On Tuesday, Stifel downgraded the stock from Buy to Hold with a price target lowered from CA$12 ($8.95) to CA$8, seeing the company’s latest postponement of financial results as a sign of a “larger issue.”
The Cronos Analyst
MKM Partners’ Bill Kirk upgraded Cronos from Neutral to Buy and lowered the price target from CA$12 to CA$11.
The Cronos Thesis
“We are taking advantage of broad market concerns and weakness related to 10K filing uncertainty, to upgrade Cronos to Buy,” Kirk said in the Wednesday upgrade note. (See his track record here.)
The source of the Cronos filing issue — bulk wholesale — does not carry strategic significance and is a "non-core part of Cronos' business," the analyst said.
“Even if all the wholesale revenue and profitability didn't exist (unlikely), we still think there is compelling value.”
The company has 75% of its market cap, or CA$41.9 billion, in net cash and equivalents; has a demonstrated history of keeping its promises; and has the advantage of a relationship with Altria Group MO, he said.
An examination of transcripts from six Canadian licensed producers going back to 2017 found that, on average, industry projections were accurate half of the time, while Cronos was correct 68% of the time, Kirk said.
“This gives us more confidence that the filing delays are not indicative of broader issues.”
Altria is the “most important vendor into U.S. convenience stores and likely has more points of distribution than any CPG company,” the analyst said.
“We take our 4Q numbers down to account for uncertainty and realize prior period adjustments may be necessary.”
CRON Price Action
The stock was trading 3.2% higher at $5.49 at the time of publication Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.